...
首页> 外文期刊>Nature Communications >DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis
【24h】

DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis

机译:临床上与多发性硬化症不一致的单卵双胞胎的DNA甲基化特征

获取原文
           

摘要

Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system with a modest concordance rate in monozygotic twins, which strongly argues for involvement of epigenetic factors. We observe highly similar peripheral blood mononuclear cell-based methylomes in 45 MS-discordant monozygotic twins. Nevertheless, we identify seven MS-associated differentially methylated positions (DMPs) of which we validate two, including a region in the TMEM232 promoter and ZBTB16 enhancer. In CD4?+?T cells we find an MS-associated differentially methylated region in FIRRE. Additionally, 45 regions show large methylation differences in individual pairs, but they do not clearly associate with MS. Furthermore, we present epigenetic biomarkers for current interferon-beta treatment, and extensive validation shows that the ZBTB16 DMP is a signature for prior glucocorticoid treatment. Taken together, this study represents an important reference for epigenomic MS studies, identifies new candidate epigenetic markers, and highlights treatment effects and genetic background as major confounders.
机译:多发性硬化症(MS)是中枢神经系统的炎症性脱髓鞘疾病,在单卵双胞胎中适度的一致率,这强烈地证明了表观遗传因素的参与。我们在45名MS不一致的单卵双胞胎中观察到高度相似的外周血基于单核细胞的甲基化组。但是,我们确定了七个与MS相关的甲基化差异位置(DMP),我们验证了两个位置,包括TMEM232启动子和ZBTB16增强子中的一个区域。在CD4 + + T细胞中,我们在FIRRE中发现了MS相关的差异甲基化区域。此外,有45个区域在各个对中显示出较大的甲基化差异,但它们与MS的关联并不明显。此外,我们介绍了当前干扰素-β治疗的表观遗传标记,广泛的验证表明ZBTB16 DMP是先前糖皮质激素治疗的标志。两者合计,这项研究代表表观基因组MS研究的重要参考,确定新的候选表观遗传标记,并强调治疗效果和遗传背景是主要混杂因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号